Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction

Circulation

Volumn 95, Issue 11, 1997, Pages 2508-2516

  Berkowitz, Scott D ^a   Granger, Christopher B ^a   Pieper, Karen S ^a   Lee, Keny L ^a   Gore, Joel M ^b   Simoons, Maarten ^c   Armstrong, Paul W ^d   Topol, Eric J ^e   Califf, Robert M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d UNIVERSITY OF ALBERTA   (Canada)

^e Duke University Medical Center ^*

Author keywords

myocardial infarction; plasminogen activators; prognosis; streptokinase; thrombolysis

Indexed keywords

PLASMINOGEN ACTIVATOR; STREPTOKINASE;

ARTICLE; BLOOD CLOT LYSIS; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; INCIDENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STROKE;

EID: 0030996174     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.11.2508     Document Type: Article

References (22)

1. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of mote than 1000 patients. Lancet. 1994:343:311-322.
2. Levine MN,Goldhaber SZ, Gore JM, Hirsh J, Califf RM. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest. 1995:108:291S-301S.
3. Rao AK, Pratt C, Berke A, Jaffe A. Ockene I. Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML, for the TIMI Investigators. Thrombolysis In Myocardial Infarction (TIMI) Trial phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988:11:1-11.
4. Califf RM, Topol EJ, George BS, Boswick JM, Abbottsmith C. Sigmon KN, Candela R, Masek R, Kereiakes D, O'Neill WW, Stack RS, Stump D, and the Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Hemorrhagic complications associated with the use of intravenous tissue plasiniogen activator in treatment of acute myocardial infarction. Am J Med. 1988;885:353-359.
5. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, Feit F, Gore JM, Hillis D, Lambrew CT, Leiboff R, Mann G, Markis JE, Pratt CM, Sharkey SW, Sopko G, Tracy RP, Chesebro JH. for the TIMI Investigators. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, aspirin for acute myocardial infarction. Ann Intern Med. 1991;115:256-265.
6. Sane DC. Califf RM, Topol EJ. Stump ED. Mark DB. Greenberg CS. Bleeding thrombolytic therapy for acute myocardial infarction: mechanisms and management. Ann Intern Med. 1989;111: 1010-1022.
7. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993:329:673-682.
8. Gore JM, Granger CB. Simoons ML, Sloan MA, Weaver WD. White HD, Barbash GI. Van de Werf F. Aylward PE. Topol EJ. Califf RM. for the GUSTO-I Investigators, Stroke after thrombolysis: mortality and functional outcomes in the USTO-1 trial. Circulation. 1995:92:2811-2818.
9. Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Simoons M, Aylward P, Van de Werf F. Califf RM, and the GUSTO-I Investigators. Predictors of 30-day mortality In the era of reperfusion for acute myocardial infarction: results from an international trial of 41 021 Paitients. Circulation. 1995:91:1659-1668.
10. Wall TC, Califf RM, Ellis SG, Sigmon K, Kereiakes D, George BS, Samaha J, Sane DC, Stump DC, Stack RS. Lack of of early catheterization and fibrin specificity on bleeding complications after thrombolytic therapy. J Am Coll Cardiol. 1993:21:597-603.
11. White HD, Burbash GI, Modan M, Simes J, Diaz R, Hampton JR, Heikkila J, Kristinsson A, Moulopoulos S, Paolasso EAC, Van der Werf T. Pehrsson K, Sandoe E, Wilcox RG, Verstraete M, von der Lippe G, Van de Werf F. After correcting for worse baseline Characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity is men except for a higher incidence of hemorrhagic stroke. Circulation. 1993;88:2097-2103.
12. Kalbfleisch J, Thadani U, LittleJohn JK, Brown G, Magorien R, Kutcher M. Taylor G, Maddox WT, Campbell WB, Perry J Jr. Spann JF, Vetovec G, Kent R, Armstrong PW. Evaluation of a prolonged infusion of recombinant tissue-type plasminogen activator (duteplase) in preventing reocclusion following successful thrombolysis in acute myocardial infarction. Am J Cardiol. 1992;69:1120-1127.
13. Stone GW, Grines CL, Browne KF, Marco J, Rothbaum D, O'Keefe J, Hartzler GO, Overlie P, Donohue B, Chelliah N, Vliestra R, Puchrowicz-Ochocki S, O'Neill WW. Comparison of in-hospital outcome in men venus women treated by either thrombolytic therapy or primary coronary angioplasty for acute myocardial infarction. Am J Cardiol. 1995:75:987-992.
14. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardioco. GISSI-2: in-hospital mortality clinical course of 20891 patients with suspected acute myocardial infarction randomised between alteplase streptokinase with or without Lancet. 1990:336:7l-75.
15. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. IS1S-3: a randomised of comprison of streptokinase vs tissue plasminogen activator vs anistreplase of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet. 1993:339:753-770.
16. Collen D. Biological properties of plasminogen activators. In: Sobel BE, Collen D, Grossbard EB, eds. Tissue Plasninogen Activator in Thrombolytic Therapy. New York, NY: Dekker Inc: 1987:3-24.
17. Kamat SG, Michelson AD, Benoit SE, Moake JL, Rajasekhar D, Hellums JD, Kroll MH, Schafer AI. Fibrinolysis inhibits shear stress-induced platelet aggregation. Circulation. 1995:92:1399-1407.
18. Federici AB, Berkowitz SD, Zimmerman TS. Mannucci PM. Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction. Blood. 1992;79:38-44.
19. Stricker RB, Wong D, Shiu DT. Reyes PT Shuman MA. Activation of plasminogen by tissue plasminogen activator OB normal and thrombosthenic platelets: effect of surface proteins and platelet aggregation. Blood, 1986;68:275-280.
20. Simoons ML, Maggioni AP, Knatterud G, Leimberger JD, de Jaegere P. Domburgh R. Boersma E, Franzosi MG, Califf R, Schroder R, Braunwald E. Individual risk assessment for intracrnial haemorrhage during thrombolytic therapy. Lancet. 1993:342:1523-1528.
21. Weaver WD. White HD. Wilcox RG. Aylward PE. Morris D, Guerci A. Ohman EM, Barbash GI, Betriu A. Sadowski Z, Topol EJ. Califf RM, for the GUSTO-I Investigators. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. JAMA. 1996;275:777-782.
22. Ohman EM, Califf RM, George BS, Quigley PJ, Kereiakes DJ, Harrelson-Woodlief L, Candela RJ, Flanagan C. Stack RS, Topol EJ. The use of intraaortic balloon pumping as an adjunct to reperfusion therapy in acute myocardial infarction. Am Heart J. 1991;121:895-901.